Darunavir: A comprehensive profile.

Ibrahim A Darwish, Abdulrahman A Al-Majed, Nawaf A Alsaif, Ahmed H Bakheit, Rashed N Herqash, Abdullah Alzaid

Profiles of drug substances, excipients, and related methodology 2021

filter terms:

Darunavir: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl] (isobutyl)amino}-3-hydroxy-1-phenyl-2-butanyl]carbamate is a synthetic non-peptide protease inhibitor. On June 2006, it was first approved by the Food and Drug administration (FDA) for treatment of resistant type-1 of the human immunodeficiency virus (HIV). In July 2016, the FDA expanded the approval for use of darunavir in pregnant women with HIV infection. Darunavir prevents the replication of HIV virus by inhibiting the catalytic activity of the HIV-1 protease enzyme, and selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in virus-infected cells, which prevents the formation of mature infectious virus particles. Darunavir is unique among currently available protease inhibitors because it maintains antiretroviral activity against a variety of multidrug-resistant HIV strains. This article discusses, by a critical extensive review of the literature, the description of darunavir in terms of its names, formulae, elemental composition, appearance, and use in the treatment of HIV-infected patients. The article also discusses the methods for preparation of darunavir, its physical-chemical properties, analytical methods for its determination, pharmacological properties, and dosing information. © 2021 Elsevier Inc. All rights reserved.

Citation

Ibrahim A Darwish, Abdulrahman A Al-Majed, Nawaf A Alsaif, Ahmed H Bakheit, Rashed N Herqash, Abdullah Alzaid. Darunavir: A comprehensive profile. Profiles of drug substances, excipients, and related methodology. 2021;46:1-50